Kamada Remains Focused on Lung Treatment: CEO Tsur

The transcript discusses the failure of a trial for an inhaled version of A1 treatment, which affects hereditary emphysema. The company plans to meet with the European Agency for conditional approval due to unmet needs. Despite investor concerns about the inhaled treatment's potential revenue loss, the company aims to create value from existing data and continue clinical development. Kamada has a strong business base with products in 15 countries and strategic partnerships. The intravenous version of the treatment is a growing market, and the company has a promising pipeline, including treatments for rabies, cystic fibrosis, and diabetes. Financially, Kamada is stable with sufficient cash flow to support development.

What are the implications of the failure of the inhaled version of the A1 treatment?

How does the company plan to create value from the data they have?

What are the key products and markets that Kamada is focusing on?

What is the significance of the intravenous version of the treatment for Kamada?

What is the current status of Kamada's clinical trials for type one diabetes?